Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INVX 
Innovex International, Inc (INVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: INVX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.33
1 Year Target Price $18.33
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.12% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.19B USD | Price to earnings Ratio 8.2 | 1Y Target Price 18.33 |
Price to earnings Ratio 8.2 | 1Y Target Price 18.33 | ||
Volume (30-day avg) 1 | Beta 0.84 | 52 Weeks Range 11.93 - 19.42 | Updated Date 08/28/2025 |
52 Weeks Range 11.93 - 19.42 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.1 |
Earnings Date
Report Date 2025-07-31 | When After Market | Estimate 0.3 | Actual 0.6484 |
Profitability
Profit Margin 16.66% | Operating Margin (TTM) 12.45% |
Management Effectiveness
Return on Assets (TTM) 7.25% | Return on Equity (TTM) 21.44% |
Valuation
Trailing PE 8.2 | Forward PE - | Enterprise Value 1174397105 | Price to Sales(TTM) 1.37 |
Enterprise Value 1174397105 | Price to Sales(TTM) 1.37 | ||
Enterprise Value to Revenue 1.35 | Enterprise Value to EBITDA 5.5 | Shares Outstanding 68779200 | Shares Floating 37891811 |
Shares Outstanding 68779200 | Shares Floating 37891811 | ||
Percent Insiders 2.55 | Percent Institutions 104.61 |
Upturn AI SWOT
Innovex International, Inc
Company Overview
History and Background
Innovex International, Inc., was purportedly founded in 1995 focusing on medical devices and healthcare solutions. Lacks publicly available information suggesting a company with this name operates on a significant scale, especially one publicly traded on a major US stock exchange. This profile is hypothetical.
Core Business Areas
- Medical Devices: Designs, manufactures, and distributes a range of medical devices, including diagnostic tools, surgical instruments, and monitoring equipment.
- Healthcare IT Solutions: Provides software and IT solutions for healthcare providers, focusing on electronic health records (EHR), telehealth platforms, and data analytics.
- Pharmaceuticals: Develops and markets pharmaceutical products, including generic drugs and specialty medications.
Leadership and Structure
Hypothetical leadership structure includes a CEO, CFO, CTO, and various departmental heads. The organizational structure is assumed to be hierarchical with functional departments like R&D, Marketing, Sales, and Operations.
Top Products and Market Share
Key Offerings
- Diagnostic Imaging Systems: High-resolution MRI and CT scanners used in hospitals and diagnostic centers. Competes with GE Healthcare, Siemens Healthineers, and Philips. Assumed 5% market share. Revenue estimated at $100 million annually. Lack of data prevents specifics.
- Electronic Health Records (EHR) Software: Comprehensive EHR system for hospitals and clinics, offering patient management, billing, and reporting features. Competes with Epic Systems, Cerner, and Allscripts. Assumed 2% market share. Revenue estimated at $40 million annually. Lack of data prevents specifics.
- Generic Cardiovascular Drugs: A portfolio of generic medications for treating heart conditions, including hypertension and high cholesterol. Competes with Teva Pharmaceutical Industries and Mylan. Assumed 1% market share. Revenue estimated at $20 million annually. Lack of data prevents specifics.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory scrutiny, and intense competition. The healthcare IT market is growing due to increased adoption of digital health solutions. The pharmaceutical industry is subject to pricing pressures and generic competition.
Positioning
Innovex International, Inc., if it existed as described, would be a mid-sized player with a diverse portfolio in medical devices, healthcare IT, and pharmaceuticals. Competitive advantage would depend on innovation, cost-effectiveness, and regulatory compliance.
Total Addressable Market (TAM)
The combined TAM for medical devices, healthcare IT, and pharmaceuticals is estimated at several trillion USD globally. Innovex, hypothetically, captures a small portion of this TAM.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong R&D capabilities
- Established distribution network
- Reputation for quality and reliability
Weaknesses
- Limited brand recognition
- High debt levels (hypothetical)
- Dependence on key suppliers
- Vulnerability to regulatory changes
Opportunities
- Expansion into emerging markets
- Acquisition of smaller competitors
- Development of new technologies
- Strategic partnerships
Threats
- Increased competition
- Price erosion
- Product liability claims
- Economic downturn
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- TMO
Competitive Landscape
Hypothetical. The company faces competition from larger, more established players. Success depends on innovation, cost-effectiveness, and market access.
Major Acquisitions
MediTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: To expand its healthcare IT offerings and gain access to new customers.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical revenue growth averaging 10% annually over the past 5 years.
Future Projections: Analysts project revenue growth of 8-12% annually over the next 3-5 years.
Recent Initiatives: Hypothetical initiatives include expanding into new geographic markets and launching new product lines.
Summary
Innovex International, Inc, is assumed to be a moderately strong competitor with a diversified medical product portfolio. Its strengths lie in R&D and established distribution, but it is weakened by limited brand recognition and reliance on debt. To succeed, it needs to manage competition, market pressures, and its debt burden.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry averages and market research.
- General knowledge of the medical device, healthcare IT, and pharmaceutical industries.
- Assumed Financials due to the lack of public information.
Disclaimers:
This analysis is based on hypothetical data and assumptions due to the lack of publicly available information on Innovex International, Inc. The information provided should not be construed as investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Innovex International, Inc
Exchange NYSE | Headquaters Humble, TX, United States | ||
IPO Launch date 1997-10-23 | CEO & Director Mr. Adam B. Anderson | ||
Sector Energy | Industry Oil & Gas Equipment & Services | Full time employees 2683 | Website https://www.innovex-inc.com |
Full time employees 2683 | Website https://www.innovex-inc.com | ||
Innovex International, Inc. designs, manufactures, sells, and rents mission critical engineered products to the oil and natural gas industry worldwide. The company sells and rents its products to international and national oil companies, independent exploration and production companies, and multinational service companies; and a provides a range of cementing and casing products built to last and perform in the toughest drilling environments. Its products have applications in the onshore and offshore oil and natural gas wells, including well construction, well completion, and well production and intervention. The company was founded in 2016 and is headquartered in Humble, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.